Davis Ira D, Ho Martin, Hupertz Vera, Avner Ellis D
Rainbow Center for Childhood PKD, Department of Pediatrics, Rainbow Babies and Children's Hospital, Case Western Reserve University School of Medicine, Cleveland, OH 44106-6003, USA.
Pediatr Transplant. 2003 Oct;7(5):364-9. doi: 10.1034/j.1399-3046.2003.00094.x.
Childhood PKD encompasses the diagnoses of AR and ADPKD, glomerulocystic disease, and syndromes such as tuberous sclerosis or Jeune's syndrome. Given the fact that a majority of PKD children with ESRD carry the diagnosis of ARPKD, natural history studies assessing the long-term prognosis of PKD patients following renal transplantation must focus on morbidity and mortality issues related to complications from congenital hepatic fibrosis. Using the NAPRTCS registry, we analyzed the patient and graft survival rates of 203 PKD patients and 7044 non-PKD patients undergoing renal transplantation between 1987 and 2001. Deceased PKD patients, all with a diagnosis of ARPKD, were further identified and characterized using a special questionnaire submitted to the principal investigators. Overall graft and patient survival rates were not significantly different between PKD and non-PKD patients. No differences in rates of acute rejection or time to first rejection were noted between PKD and non-PKD patients. The relative risk of living longer than 3 yr in the PKD patients was not significantly different from non-PKD patients (RR = 0.70, p = 0.28). Sepsis was identified as a likely factor in the cause of death in nine (64%) ARPKD patients and was comfirmed with a positive blood culture in four patients. Despite similar graft and patient survival rates among PKD and non-PKD children following renal transplantation, our results suggest that ARPKD transplant recipients appear to be at increased risk for sepsis that may be related to hepatic fibrosis and ascending cholangitis. The utility of early liver transplantation in ARPKD patients with significant hepatobiliary disease is discussed.
儿童多囊肾病包括常染色体隐性遗传型多囊肾病(ARPKD)、常染色体显性遗传型多囊肾病(ADPKD)、肾小球囊性疾病以及结节性硬化症或约内氏综合征等综合征。鉴于大多数终末期肾病(ESRD)的多囊肾病儿童被诊断为ARPKD,评估肾移植后多囊肾病患者长期预后的自然史研究必须关注与先天性肝纤维化并发症相关的发病率和死亡率问题。利用北美儿科肾脏移植协作研究(NAPRTCS)登记处的数据,我们分析了1987年至2001年间接受肾移植的203例多囊肾病患者和7044例非多囊肾病患者的患者及移植物存活率。已故的多囊肾病患者均被诊断为ARPKD,通过向主要研究者提交的一份特殊问卷对其进行了进一步识别和特征描述。多囊肾病患者和非多囊肾病患者的总体移植物及患者存活率无显著差异。多囊肾病患者和非多囊肾病患者在急性排斥反应发生率或首次排斥反应时间方面未发现差异。多囊肾病患者存活超过3年的相对风险与非多囊肾病患者无显著差异(相对风险RR = 0.70,p = 0.28)。脓毒症被确定为9例(64%)ARPKD患者死亡原因中的一个可能因素,4例患者血培养呈阳性,从而得以证实。尽管肾移植后多囊肾病儿童和非多囊肾病儿童的移植物及患者存活率相似,但我们的结果表明,ARPKD移植受者发生脓毒症的风险似乎增加,这可能与肝纤维化和上行性胆管炎有关。本文还讨论了早期肝移植对患有严重肝胆疾病的ARPKD患者的作用。